Home| Features| About| Customer Support| Request Demo| Our Analysts| Login
Gallery inside!
Markets

Wednesday’s Biggest Analyst Calls: Nvidia, Apple, Tesla, Visa, Disney, Microsoft, Expedia, Ollie’s & More

December 18, 2024
minute read

Here are the biggest calls on Wall Street on Wednesday:

DA Davidson Initiates Coverage on Box with a Buy Rating

DA Davidson has initiated coverage on Box, a content solutions provider, assigning it a “Buy” rating with a $45 price target. The firm anticipates accelerating growth for the company in the coming years.

Citi Upgrades Ollie’s Bargain Outlet to Buy

Citi has upgraded Ollie’s from “Sell” to “Buy,” citing the discount retailer’s strong positioning in an uncertain economic environment. The firm has set a price target of $133, based on approximately 30x estimated earnings per share for fiscal year 2026.

Morgan Stanley Highlights Disney as a Top Pick for 2025

Morgan Stanley has named Disney a top pick for 2025, forecasting significant profits in streaming for both Disney and Warner Bros. Discovery.

Liberty Formula One Upgraded to Overweight by Morgan Stanley

Morgan Stanley upgraded Liberty Formula One from “Equal Weight” to “Overweight,” citing expectations for “higher growth for longer.” The firm raised its price target from $95 to $115.

Evercore ISI Upgrades Dow to Outperform

Evercore ISI has upgraded Dow from “In Line” to “Outperform,” stating that the chemical company offers an attractive risk-reward profile and improved visibility.

Bernstein Names Amazon a 2025 Top Pick

Bernstein has identified Amazon as a key player for 2025, describing it as a durable leader in the cloud and well-positioned in the AI space.

Piper Sandler Reiterates Nvidia as Overweight

Piper Sandler reiterated its “Overweight” rating for Nvidia, emphasizing its leadership in AI accelerators and the anticipated launch of its Blackwell architecture. The firm considers Nvidia a top large-cap pick heading into 2025.

UBS Maintains Microsoft as a Buy

UBS has reiterated a “Buy” rating for Microsoft, increasing its price target from $500 to $525 per share. While sentiment around the stock is improving, concerns remain about Azure’s supply issues, capital expenditures, and the evolution of its relationship with OpenAI.

JPMorgan Bullish on Amazon, Meta, and Alphabet for 2025

JPMorgan has highlighted Amazon, Meta, and Alphabet as its top picks for 2025, projecting increased capital expenditures driven by AI advancements. The firm expects above-consensus spending levels of $97 billion for Amazon, $64 billion for Meta, and $62 billion for Alphabet.

Goldman Sachs Upgrades MSCI to Buy

Goldman Sachs upgraded MSCI from “Neutral” to “Buy,” citing better buy-side conditions. The firm raised its 12-month price target from $617 to $723.

Baird Downgrades Rivian to Neutral

Baird downgraded Rivian from “Outperform” to “Neutral,” pointing to a lack of near-term catalysts. Despite positive long-term prospects, the firm expects EV sales to underperform relative to expectations.

Goldman Sachs Initiates Lantheus Holdings as Buy

Goldman Sachs initiated coverage of Lantheus Holdings with a positive outlook, emphasizing growth potential for its prostate cancer diagnostic agent, Pylarify. The firm sees the stock as undervalued at current levels.

Citi Starts Academy Sports with a Buy Rating

Citi initiated coverage of Academy Sports with a “Buy” rating, citing significant growth potential as the sporting goods retailer expands beyond its 298-store footprint.

Barclays Upgrades Transocean to Overweight

Barclays upgraded Transocean from “Equal Weight” to “Overweight,” noting steady debt reduction. The firm’s price target remains at $4.50, offering 23% upside from current levels.

JPMorgan Upgrades Xometry to Overweight

JPMorgan upgraded Xometry, an on-demand industrial parts marketplace, from “Neutral” to “Overweight.” The firm raised its price target for December 2025 from $25 to $45, citing strong profitability potential.

Stephens Upgrades Fiserv to Overweight

Stephens upgraded Fiserv from “Equal Weight” to “Overweight,” raising its price target to $255 from $220. The firm highlighted the financial services company’s high-quality business model.

Bank of America Upgrades Expedia to Buy

Bank of America upgraded Expedia from “Neutral” to “Buy,” describing it as a “top Internet value stock.” The firm sees potential for the valuation gap between Expedia and Booking Holdings to narrow by 2025.

Baird Reiterates Tesla as Outperform

Baird reaffirmed its “Outperform” rating for Tesla, advising investors to capitalize on price dips as the stock gains momentum and approaches potential catalysts in 2025.

Evercore ISI Provides Tactical Outperform for Best Buy

Evercore ISI maintained its “In Line” rating for Best Buy but added a tactical outperform based on holiday shopping trends. The firm sees short-term upside to $95-$100.

Evercore ISI Issues Tactical Outperform for Target

Evercore ISI also initiated a positive tactical trade for Target, citing improved holiday shopping intentions and increased web traffic in December.

KeyBanc Upgrades Bill.com to Overweight

KeyBanc upgraded Bill.com from “Sector Weight” to “Overweight,” noting signs of recovery after headwinds in the payments sector. The firm expressed optimism about the company’s profitability trajectory.

Daiwa Reiterates Apple as Outperform

Daiwa reiterated an “Outperform” rating for Apple and raised its price target from $255 to $275. The firm highlighted the potential for a significant AI-driven upgrade cycle.

Morgan Stanley Names Visa a Top Pick

Morgan Stanley designated Visa as a top pick for 2025, citing attractive valuation, regulatory relief, and growth opportunities in travel and value-added services.

Raymond James Initiates DoubleVerify as Outperform

Raymond James initiated coverage of DoubleVerify Holdings with an “Outperform” rating, calling the software company a market leader in digital advertising services.

Jefferies Recommends Rocket Pharmaceuticals as Buy

Jefferies initiated coverage of Rocket Pharmaceuticals with a “Buy” rating, praising its portfolio of gene therapies targeting rare and severe diseases.

Tags:
Author
Editorial Board
Contributor
Eric Ng
Contributor
John Liu
Contributor
Editorial Board
Contributor
Bryan Curtis
Contributor
Adan Harris
Managing Editor
Cathy Hills
Associate Editor

Subscribe to our newsletter!

As a leading independent research provider, TradeAlgo keeps you connected from anywhere.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Explore
Related posts.